Diabetes Performance Measures: Current Status and Future Directions von O'CONNOR, Patrick J, BODKIN, Noni L, TAYLOR, Michael L, WYSHAM, Carol H, FRADKIN, Judith, GLASGOW, Russell E, GREENFIELD, Sheldon, GREGG, Edward, KERR, Eve A, PAWLSON, L. Gregory, SELBY, Joseph V, SUTHERLAND, John E

Volltext

In reply—Long-term Efficacy and Safety of Exenatide Treatment von Wysham, Carol H., MD

Volltext

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data von Young, James B, Gauthier-Loiselle, Marjolaine, Bailey, Robert A, Manceur, Ameur M, Lefebvre, Patrick, Greenberg, Morris, Lafeuille, Marie-Hélène, Duh, Mei Sheng, Bookhart, Brahim, Wysham, Carol H

Volltext

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week... von Wysham, Carol H, Rosenstock, Julio, Vetter, Marion L, Wang, Hui, Hardy, Elise, Iqbal, Nayyar

Volltext

Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial von Wysham, Carol H, MacConell, Leigh, Hardy, Elise

Volltext

743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials von WYSHAM, CAROL H., TOFE, SANTIAGO, SAPIN, HELENE, MALIK, RALEIGH, NEFF, LISA M.

Volltext

Five-Year Efficacy and Safety Data of Exenatide Once Weekly von Wysham, Carol H., MD, MacConell, Leigh A., PhD, Maggs, David G., MD, Zhou, Ming, PhD, Griffin, Peter S., BA, Trautmann, Michael E., MD

Volltext

Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study von Philis-Tsimikas, Athena, Wysham, Carol H., Hardy, Elise, Han, Jenny, Iqbal, Nayyar

Volltext

100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes... von ROSENSTOCK, JULIO, WYSHAM, CAROL H., FRIAS, JUAN P., KANEKO, SHIZUKA, LEE, CLARE, LANDO, LAURA FERNANDEZ, MAO, HUZHANG, CUI, XUEWEI, THIEU, VIVIAN

Volltext

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors von Wysham, Carol H, Lefebvre, Patrick, Pilon, Dominic, Ingham, Mike, Lafeuille, Marie-Hélène, Emond, Bruno, Kamstra, Rhiannon, Chow, Wing, Pfeifer, Michael, Duh, Mei Sheng

Volltext

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like... von Wysham, Carol H, Campos, Carlos, Kruger, Davida

Volltext

Target Fasting Plasma Glucose (FPG) without Nocturnal Hypoglycemia in Patients with Type 1 Diabetes or Type 2 Diabetes—Results from SWITCH Trials von Wysham, Carol H, Lane, Wendy, Ladelund, Steen, Tutkunkardas, Deniz, Heller, Simon

Volltext

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes von Wysham, Carol H., Rosenstock, Julio, Vetter, Marion L., Dong, Fang, Öhman, Peter, Iqbal, Nayyar

Volltext

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial von Wysham, Carol H, MacConell, Leigh A, Maggs, David G, Zhou, Ming, Griffin, Peter S, Trautmann, Michael E

Volltext

Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes von Miller, Eden M, Wysham, Carol H

Volltext

Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals von LaRue, Susan, Springer, Jane, Noderer, Michael, Meehan, James, Wysham, Carol H.

Volltext

Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice von Wysham, Carol H, Kruger, Davida F

Volltext

1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program von MATTHEWS, DAVID R., WYSHAM, CAROL H., DAVIES, MELANIE J., SLEE, APRIL, ALBA, MARIA, LEE, MARY, CAPUANO, GEORGE, PERKOVIC, VLADO, MAHAFFEY, KENNETH W., NEAL, BRUCE

Volltext

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysi... von DeVries, J. Hans, Bailey, Timothy S., Bhargava, Anuj, Gerety, Gregg, Gumprecht, Janusz, Heller, Simon, Lane, Wendy, Wysham, Carol H., Zinman, Bernard, Bak, Britta A., Hachmann‐Nielsen, Elise, Philis‐Tsimikas, Athena

Volltext

Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers von Kuritzky, Louis, Reid, Timothy S, Wysham, Carol H

Volltext